Stocks · News reference
Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure
The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation study to evaluate the safety and pharmacokinetics of topical sildenafil cream in healthy postmenopausal women,"
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001401914/000140191426000052/dare-20260928.htm
8-K filing — Dare Bioscience, Inc. (DARE)
Filed: 2026-10-02 AccNo: 0001401914-26-000052 Size: 139 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the issuance of